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Background: MicroRNAs are known to inhibit gene expression by binding to the 3′UTR of the target transcript.
Downregulation of miR-223 has been recently reported to have prognostic significance in CLL. However, there is
no evidence of the pathogenetic mechanism of this miRNA in CLL patients.
Methods: By applying next-generation sequencing techniques we have detected a common polymorphism (rs2307842),
in 24% of CLL patients, which disrupts the binding site for miR-223 in HSP90B1 3′UTR. We investigated whether miR-223
directly targets HSP90B1 through luciferase assays and ectopic expression of miR-223. Quantitative real-time polymerase
chain reaction and western blot were used to determine HSP90B1 expression in CLL patients. The relationship between
rs2307842 status, HSP90B1 expression and clinico-biological data were assessed.
Results: HSP90B1 is a direct target for miR-223 by interaction with the putative miR-223 binding site. The analysis in
paired samples (CD19+ fraction cell and non-CD19+ fraction cell) showed that the presence of rs2307842 and IGHV
unmutated genes determined HSP90B1 overexpression in B lymphocytes from CLL patients. These results were
confirmed at the protein level by western blot. Of note, HSP90B1 overexpression was independently predictive
of shorter time to the first therapy in CLL patients. By contrast, the presence of rs2307842 was not related to the outcome.
Conclusions: HSP90B1 is a direct target gene of miR-223. Our results provide a plausible explanation of why CLL patients
harboring miR-223 downregulation are associated with a poor outcome, pointing out HSP90B1 as a new pathogenic
mechanism in CLL and a promising therapeutic target.
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MicroRNAs (miRNAs) are endogenously expressed small
RNA molecules that mediate posttranscriptional gene
silencing through complimentary binding of the 3′un-
translated regions (3′UTR) of target genes [1]. Over half of
the human transcriptome is predicted to be under miRNA
regulation, embedding this post-transcriptional control
pathway within nearly every biological process [2-4]. Thus,
miRNAs are involved in almost all aspects of cancer biology,
such as proliferation, apoptosis, invasion/metastasis, and
angiogenesis [5].* Correspondence: jmhr@usal.es
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article, unless otherwise stated.Over the past few years several studies have shown that
miRNAs play an important role in CLL [6-9]. Distinct
microRNA signatures are associated with prognosis, dis-
ease progression [9-14] and response to treatment [15,16].
In CLL, the downregulation of miR-223 is associated with
disease aggressiveness and poor prognostic factors [13,14],
which may become this miRNA a new reliable prognostic
predictor. However, unlike other miRNAs with prognostic
value in CLL such as miR-181b and miR- 29c, there is no
evidence of its pathogenetic role, and no target has so far
been proposed or validated for miR-223 in CLL.
Over the last decade, several studies have implicated heat
shock proteins (HSPs) as major contributors to cancer pro-
gression and the development of chemoresistance. HSPs
are upregulated in many cancers, including CLL, and mayed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Clinical and biological features of the CLL
patients included in the study
Parameter Category
Age (years), median (range) 66 (34-90)
Gender Male 66.0%
White blood cells/mL (range) 21 545 (7 080-188 020)
Lymphocytes/mL (range) 15 741 (1 580-180 000)
Hemoglobin, g/dL (range) 14.1 (4.4-16.8)
Platelet count/mL (range) 171 500 (23 000-399 000)
IGHV Unmutated 50.3%
Binet stage A 65.9%
B 23.2%
C 10.9%
LDH Normal 81.6%
High 18.4%
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mechanisms that remain to be fully described [17-19]. Pre-
clinical studies in CLL have shown that HSP90 inhibition
causes the degradation of ZAP-70 and other proteins asso-
ciated with poor survival, and this may ultimately lead to
apoptosis [20-24]. Targeting HSP90 is an attractive strategy
in CLL as this could represent a therapeutic option to drug
resistance in CLL associated with lesions in the ATM/TP53
pathway [25-27]. Thus, inhibitors of HSP90 have been pro-
posed as a novel therapeutic option for CLL [28-30].
By applying next-generation sequencing (NGS) tech-
niques we have detected a common polymorphism
(rs2307842), in 24% of CLL patients, which disrupts
the binding site for miR-223 in HSP90B1 3′UTR, leading to
its overexpression in clonal B lymphocytes. This finding has
helped us to identify miR-223 as a regulator of HSP90B1
levels in CLL patients, with therapeutic consequences.b2microglobulin Normal 55.9%
High 44.1%
Bone marrow pattern Diffuse 41.9%
Other 58.1%
Hepatomegaly Yes 10.5%
No 89.5%
Splenomegaly Yes 26.5%
No 73.5%
B symptoms Yes 13.5%
No 86.5%
Dead during follow-up Yes 21.6%
No 78.4%
Therapy during follow-up Yes 45.7%
No 78.4%
Results expressed as median or percentages.
IGHV: immunoglobulin heavy variable gene; LDH: lactate dehydrogenase.Methods
Patients and controls
Four patients with CLL were selected for a Targeted Se-
quence Capture and DNA Sequencing assay. CLL diagnosis
was performed according to World Health Organization
(WHO) classification [31] and Working Group of National
Cancer Institute (NCI) criteria [32]. CD19+ fraction cells
were used for sequencing and were obtained before admin-
istration of any treatment. To determine the clinical impact
of HSP90B1 3′UTR polymorphism, we expanded the study
to 165 additional patients with CLL and 32 healthy
controls. FISH studies and IGHV mutational status
were assessed. Details on the main characteristics of
the 169 CLL patients included in the study are reported in
Table 1 and Additional file 1: Supplementary Methods. The
study was approved by the local ethical committee “Comité
Ético de Investigación Clínica, Hospital Universitario de
Salamanca”. Written informed consent was obtained from
each patient before they entered the study.Cells and culture conditions
The human cell lines NCI-H929 and MM1S were ac-
quired from the ATCC (American Type Culture Collec-
tion). Cell lines identity was confirmed periodically by
STR analysis, PowerPlex 16 HS System kit (www.pro-
mega.com) and online STR matching analysis (www.
dsmz.de/fp/cgi-bin/str.html). The human STR profile
database includes data sets of 2455 cell lines from
ATCC, DSMZ, JCRB and RIKEN. Both cell lines were
cultured in RPMI 1640 medium supplemented with
10% of fetal bovine serum and antibiotics (Gibco).
Cells were routinely checked for the presence of myco-
plasma with MycoAlert kit (Lonza GmBH) and only
mycoplasma-free cells were used in the experiments.
The phenotypic and cytogenetic identities of the celllines were verified by flow cytometry and FISH before
the experiments.
Details on collection and preparation of patients and
cell culture samples are available in Additional file 1:
Supplementary Methods.
Targeted sequence capture and DNA sequencing assays
We applied array-based sequence capture (Roche
NimbleGen) followed by next-generation sequencing
(Roche GS FLX Titanium sequencing platform) to
analyze a large panel of genes of relevance in CLL
(Additional file 2: Table S1) and two chromosomal re-
gions: 13q14.3 (50043128–50382849 bp) and 17p13.1
(7500000–7535000). The genes had been selected accord-
ing to published data and our previous gene expression
data and included, for example HSP90B1, TP53, ATM,
PHLPP1, E2F1, RAPGEF2 and PI3K. Pyrosequencing as-
says were performed to analyze the sequence for 3′UTR
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the array, 454 sequencing, coverage statistics and data
analysis, as well as the pyrosequencing assays are provided
in the Additional file 1: Supplementary Methods and
Additional file 2: Table S2. The sequencing data are
uploaded to the Sequence Read Archive (SRA) (http://
trace.ncbi.nlm.nih.gov/Traces/sra/) under accession num-
ber PRJNA275978. All the information is accessible with
the following link http://www.ncbi.nlm.nih.gov/bioproject/
275978.
Luciferase reporter assay
HEK293 cells were transfected with 500 ng of the con-
structs detailed in the Additional file 1: Supplementary
Methods and Additional file 2: Table S3, and cotransfected
with 25 nM miRNA precursor molecule by nucleofection,
using the HEK293 cell line program in the Amaxa II
nucleofector system. Cells were collected 24 hours after
transfection and Firefly and Renilla luciferase activities were
measured using the Dual-Glo® Luciferase Assay System
(Promega) according to the manufacturer’s protocol. Mea-
surements were performed on a Tekan Infinite® F500 mi-
croplate reader. Firefly luciferase activity was normalized
with respect to Renilla luciferase activity.
Transfection with synthetic miRNAs
H929 and MM1S cell lines were transfected with Pre-miR™
miRNA precursors pre-miR-223 or pre-miR™ miRNA-
negative, non-targeting control#1 (Ambion) at 50 nM con-
centration, using the nucleofector II system with C-16
program and Q-023 program, respectively (Amaxa). Trans-
fection efficiency was assessed with Block-iT™ Fluorescent
Oligo (Invitrogen) by flow cytometry.
Quantitative real-time polymerase chain reaction analysis
and Immunoblotting
This methodology is provided in Additional file 1: Supple-
mentary Methods.
Statistical analysis
Statistical analysis was performed using SPSS (v20). The
two-sided Student’s t test was used to analyze differences
between means (presented here with SD) of different exper-
iments, based on triplicate determinations. Differences be-
tween the results of the qRT-PCR experiments with CLL
patients were analyzed with the Mann-Whitney U. Kaplan-
Meier analysis with the Log Rank test and Cox regression
were used for survival analysis examining the impact of
HSP90B1 expression on OS and TFT. Chi-squared and
Mann–Whitney U tests were employed when appropriate
to correlate a range of biomarkers and clinical data accord-
ing to rs2307842 status and HSP90B1 expression. The
results were considered statistically significant at P < 0.05.Results
A targeted genome capture and next-generation sequencing
strategy identifies a common polymorphism in 3′UTR of
HSP90B1
Using a custom NimbleGen array we captured and se-
quenced 93 genes and two entire chromosomal regions of
four CLL patients. The enrichment assay followed by
NGS allowed the detection of over 1600 variations/sample
(median 1721, range 1618–1823). All putative variants
were first compared with published single nucleotide poly-
morphism (SNP) data (dbSNP build 130; http://www.ncbi.
nlm.nih.gov/projects/SNP). Most of the variants detected
were identified as known SNPs and 226 variants were
present in all the patients, so these were discarded. Overall,
10% of variants detected in each sample were not previ-
ously described mutations. Seventy-three missense varia-
tions affecting 33 genes were detected. Most of the genes
had one (70%) or two (12%) variations. Results are summa-
rized in Additional file 2: Table S4.
By applying a custom-made data analysis pipeline, we
have annotated the detected variants, including reported
single-nucleotide polymorphisms (SNPs), genomic loca-
tion, predicted miRNA binding sites, consequences of
the variant in transcripts (i.e. synonymous, missense)
and protein function prediction for those variants that
are predicted to result in an aminoacid sustitution. In one
out of four CLL patients (25%) we identified a 4-bp in-
sertion/deletion polymorphism (−/GACT) in 3′UTR of
HSP90B1, filled as rs2307842 (102865778-102865781b) in
the NCBI SNP database. Rs2307842 results in the deletion
of four nucleotides in 3′UTR sequence, three of them
being part of the predicted binding site for miR-223
(Figure 1A). According to the databases, UCSC Genome
Browser, NCBI and Ensembl, the reference genome con-
tains the ′GACT′ sequence. The major allele in the
European population, according to the NCBI SNP data-
base, is ′GACT′ (allele frequency: 0.79 ± 0.06), whereas the
4-bp deletion has a minor allele frequency of 0.21 ± 0.06.
Thus, we considered the individuals carrying the ′GACT′
sequence as wild-type (WT) and the individuals with the
4 bp-deletion as variants (VAR). We hypothesized that this
deletion disrupts the binding site for miR-223, thereby
increasing the translation of HSP90B1.
HSP90B1 is a direct target gene of miR-223
We have confirmed that miR-223 regulates HSP90B1 ex-
pression by 3′UTR reporter assays. First, the double-
stranded oligonucleotides, corresponding to the wild-type
(WT-3’UTR) or variant (VAR-3’UTR) miR-223 binding
site in the 3′UTR of HSP90B1 (NM_003299), were syn-
thesized. PmirGLO Vectors made up of an SV40 promoter,
the Renilla luciferase gene, and the 3′UTRs of HSP90B1
were transfected into HEK293 cells along with miR-223 or
negative control (NC) mimics. Relative luciferase activity
Figure 1 HSP90B1 is a direct target of miR-223. (A) 3′untranslated region (3′UTR) of HSP90B1 (263 nt length) with a predicted binding site for
miR-223 at 204–210 nt (grey box). The figure shows the mature miR-223 sequence (hsa-miR-223) aligned with HSP90B1 3′UTR wild type (WT, up),
and with the polymorphism (VAR, below). The seed region is shown in bold. The rs2307842 polymorphism (in grey) disrupts the putative binding
site for miR-223 by deleting the last three nucleotides of the seed region. (B) Luciferase reporter assays to confirm targeting of HSP90B1 3′UTR
by miR-223. Ectopic miR-223 expression inhibits the wild-type but not the variant HSP90B1 3′UTR reporter activity in HEK293 cells. Cells were
co-transfected with miR-223 precursor/negative control (NC) miRNA and with either wild-type (WT) or variant (VAR) HSP90B1 3′UTR reporter
construct. Luciferase activity assay was performed 24 h after transfection. The columns represent normalized relative luciferase activity by
means with 95% confidence intervals from 4 independent experiments (Mann–Whitney test, *P < 0.05). (C) and (D) Ectopic miR-223 expression
reduced both HSP90B1 mRNA (C) and protein (D) expression in H929 cell line (WT) but not in MM1S (VAR). Cells were transfected with miR-223 precursors
and negative controls. After 24 h, cells were analyzed for HSP90B1 expression by qRT-PCR (C) and western blot (D). The data shown are representative
of 3 independent experiments (Mann–Whitney test, *P < 0.05).
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the construct with wild-type 3′UTR was significantly
repressed following miR-223 transfection (P < 0.05)
(Figure 1B). However, the presence of rs2307842 poly-
morphism in 3′UTR of HSP90B1 (VAR-3′UTR) abolished
this suppression (Figure 1B), suggesting that miR-223
directly binds to this site.
We also validated HSP90B1 as a target gene of miR-223
by transfecting MM1S and H929 cell lines with miR-223/
NC mimics and then measuring HSP90B1 expression by
qRT-PCR and western blot. Sequencing assays showed
that H929 cell line has WT-3′UTR, whereas rs2307842
polymorphism was present in HSP90B1 3′UTR of MM1S
cell line (VAR-3′UTR). All experiments were done in trip-
licate. Exogenous expression of miR-223 downregulated
the expression levels of HSP90B1 in H929 cell line (WT-
3′UTR) in both mRNA (P < 0.05) and protein levels
(Figure 1C and D). By contrast, HSP90B1 expressionwas not modified in the MM1S cell line (VAR-3′UTR)
(Figure 1C and D). Taken together, all these results dem-
onstrate that HSP90B1 is a bona fide target gene of
miR-223 and that the rs2307842 polymorphism abolishes
the miR-223 regulation on HSP90B1 expression.
rs2307842 is a common polymorphism in CLL patients
To determine the clinical impact of HSP90B1 3′UTR poly-
morphism in CLL, we screened 165 additional patients with
CLL and 32 healthy controls for this polymorphism by pyro-
sequencing. A total of 50 paired DNA samples (CD19+ and
non-CD19+ fraction cells) immunomagnetically purified
from CLL patients showed complete concordance in their
3′UTR sequence, confirming that rs2307842 was the result
of a SNP and not an acquired mutation. The polymorphism
was found at a similar frequency in CLLs and healthy
controls: 41/169 (24%) in CLL patients and 8/32 (25%) in
healthy controls. These results are consistent with the
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ncbi.nlm.nih.gov/projects/SNP). Of note, no major dif-
ferences regarding clinical, biological and genetic features
were found between CLLs cases with the polymorphism
(VAR) and wild-type (WT) (Additional file 2: Table S5).miR-223 is downregulated in CLL patients with IGHV
unmutated genes
In order to corroborate the down-regulation of miR-223
previously reported in CLL patients with IGHV unmutated
(UM) genes, 53 samples were subjected to miRNA Taqman
qRT-PCR to measure miR-223 expression according to
IGHV mutation status. As expected, miR-223 was down-
regulated in UM CLL patients when compared to mutated
IGHV cases (P = 0.036).Figure 2 Hsp90b1 is upregulated in CLL patients with the
rs2307842 polymorphism and IGHV-unmutated status, as
assessed by qRT-PCR and western blot analysis. Box plots show
the relative upregulation of HSP90B1 mRNA in CLL patients with
(A) rs2307842 (VAR) and (B) IGHV unmutated genes (UM) compared
with wild-type CLL patients (WT) and the mutated cases (MUT),
respectively. The thick line inside the box plot indicates the median
expression levels and the box shows the 25th and 75th percentiles,
while the whiskers show the maximum and minimum values. Outliers
are represented by open circles. Statistical significance was determined
by the Mann–Whitney U test (P < 0.05). (C) Representative lysates of
purified B lymphocytes from CLL patients were prepared and Hsp90b1
protein levels were analyzed by western blot. B-actin served as loading
control. Representative blots from three CLL patients are shown: #1
patient with IGHV unmutated genes (UM CLL), #2 wild-type for rs2307842
and with IGHV mutated genes (WT&MUT CLL) and #3 patient with
rs2307842 (VAR CLL).HSP90B1 overexpression is observed in B lymphocytes
from CLL patients with the rs2307842 polymorphism and
IGHV-unmutated status
To test the hypothesis that HSP90B1 overexpression may
be due to a defective miR-223 regulation in CLL patients,
we analyzed HSP90B1 expression in a subgroup of pa-
tients previously characterized for the presence of the
polymorphism and IGHV mutation status.
We have performed qRT-PCR in a total of 97 CLL sam-
ples: 25 out of them were CLL patients with rs2307842
(VAR-CLLs) and 72 were wild-type (WT-CLLs). qRT-PCR
results showed that HSP90B1 was overexpressed in VAR-
CLLs (P = 0.001) (Figure 2A). To gain insight into its influ-
ence on gene expression, we have measured HSP90B1
mRNA levels in the paired normal fraction of 50 cases (13
VAR-CLLs and 37 WT-CLLs). As expected, the results
showed that B lymphocytes (tumor fraction) from VAR-
CLLs showed a higher level of HSP90B1 expression than
B lymphocytes from WT-CLLs (P = 0.001), and also from
the normal cells from the same patients (VAR-CLLs) (P <
0.001) (Additional file 3: Figure S1). However, no changes
in HSP90B1 mRNA expression were observed between
tumor and normal fractions in CLLs without the SNP
(P = 0.201). Thus, rs2307842 influenced HSP90B1 over-
expression only in the tumor fraction of the CLL patients
with the polymorphism. Of note, we also observed overex-
pression of HSP90B1 in patients with Figure 2B). The
overexpression was also confirmed in the tumor fraction
of the purified paired samples (data not shown).IGHV
unmutated genes (UM-CLLs, n = 52) in comparison with
mutated cases (MUT-CLLs, n = 45) (P = 0.003) (Figure 2B.
Hsp90b1 protein expression was also measured by
Western blot analysis in the B lymphocytes from CLL
patients harboring the variant, unmutated IGVH genes
and wild-type CLLs (Figure 2C). As expected, Hsp90b1
expression was higher in CLL with HSP90B1 the SNP
and in unmutated CLL.
Figure 3 Kaplan-Meier plot of time to first therapy of CLL patients
according to HSP90B1 expression. Patients overexpressing HSP90B1
(green line) had a significantly shorter TFT (median = 17 months; 95%CI:
5–28.9 months) as compared to that of patients with lower HSP90B1
expression levels (blue line) (median = 104 months, P= 0.024).
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to treatment
The relationship between clinical and biological character-
istics of CLL patients and HSP90B1 gene expression
was analyzed. A higher HSP90B1 mRNA expression wasTable 2 Univariate and multivariate analysis for time to first
Univariate analysis
Characteristics Events Total Median LCI
HSP9081 expression
Normal 12 39 104.0 -
High 28 39 17.0 5.0
IGVH identity
<98% 15 60 104.0 11.3
≥98% 39 57 14.0 6.8
Lymphocyte
<30000 35 90 53.0 35.1
≥30000 25 37 8.0 0.0
Cytogenetics
Good prognosis 28 82 57.0 38.3
Poor prognosis 16 21 9.0 1.7
Age (years)
≥65 29 71 42.0 18.3
<65 29 53 24.0 6.6
B symptoms
No 42 194 49.0 34.3
Yes 15 18 1.0 0.0
IGVH: immunogllobulin heavy variable gene; LCI: 95% lower confidence interval; UC
Time to first theraphy (TFT) was defined as the interval between diagnosis and thecorrelated with the presence of rs2307842 (P =0.003),
unmutated status of the IGHV gene (P = 0.008) and need
for treatment (P = 0.001) compared to that of patients
with lower HSP90B1 mRNA expression levels.
A significantly shorter time to first therapy (TFT) was
observed in the patients with HSP90B1 overexpression
(median of 17 months; 95% CI: 5–28.9 months) as com-
pared to those cases without HSP90B1 overexpression
(median of 104 months) (p = 0.024) (Figure 3). Thus,
71% of patients in the group with HSP90B1 overexpres-
sion required treatment vs. 31% of patients in the non-
overexpressed group. Other variables associated with
shorter TFT were age, non-mutated IGHV, lymphocyte
count, adverse cytogenetics and the presence of B symp-
toms (Table 2). Multivariate analysis selected HSP90B1
overexpression as an independent risk factor of TFT (HR:
2.63; 95% CI: 1.15-5.98; P = 0.021), after adjusting for IGHV
mutation status, lymphocyte count (< vs >30000), cytogen-
etics (good prognosis vs high-risk), age (< vs > 65 years) and
the presence of B symptoms.
Discussion
MicroRNAs are known to inhibit gene expression by bind-
ing to the 3′UTR of the target transcript. In the present
study HSP90B1 was validated as a miR-223 direct target by
3′UTR reporter assays and transfection with synthetic miR-
223 (Figure 1B and D). Thus HSP90B1 was overexpressedtherapy (TFT) in this series
Multivariate analysis
UCI P HR LCI UCI P
- - - - - -
28.9 0.024 2.7 1.18 6.46 0.026
196.7 - - - - -
21.2 <0.001 2.34 1.03 5.35 0.043
70.8 - - - - -
17.5 <0.001 4.2 1.75 10.05 0.001
75.7 - - - - -
16.2 <0.001 1.65 1.907 2.54 0.023
65.7 - - - - -
41.4 0.04 0.37 0.17 0.83 0.015
63.7 - - - - -
2.1 <0..001 0.17 0.06 0.53 0.002
I: 95% upper confidence interval; HR: Hazard ratio.
treatment.
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rs2307842, a common polymorphism located in HSP90B1
3′UTR, which disrupts the binding site of miR-223. More
importantly, HSP90B1 overexpression was independently
predictive of shorter time to the first therapy. We propose
that this overexpression could represent a pathogenic
mechanism for miR-223 in CLL.
Functional polymorphisms in 3′UTRs of several genes
(also known as miRSNPs or miR-polymorphisms) are as-
sociated with diseases affecting gene expression. Loss of
microRNA function due to defective miRNA-mRNA
binding results in overexpression of the target mRNA,
which can be involved in key biological processes, onco-
genic mechanisms or drug resistance [33-36]. Moreover,
the presence of some SNPs has been suggested to influ-
ence disease progression and clinical outcome in CLL
[37-42], although the results are discrepant [43-46]. Our
results showed that the presence of rs2307842, a com-
mon polymorphism located in the 3′UTR of HSP90B1
(Figure 1A), alters the interaction between the target site
in HSP90B1 and miR-223 in CLL, resulting in HSP90B1
overexpression (Figure 2A). However, no major differ-
ences regarding clinical, biological and genetic features
were found between CLLs harbouring rs2307842 and
wild-type cases (Additional file 2: Table S5).
We have also performed qRT-PCR using CD19+ periph-
eral blood lymphocytes from CLL patients displaying the
polymorphism and wild-type cases (Additional file 3:
Figure S1). As expected, B lymphocytes from CLL patients
with the polymorphism had higher levels of HSP90B1
than B lymphocytes from wild-type CLL patients. Surpris-
ingly, non-clonal cells from CLL patients with the poly-
morphism showed levels of HSP90B1 mRNA similar to
that of wild-type CLL patients (both CD19+ and non-
CD19+ fraction cells). These findings suggest that a
regulatory mechanism of HSP90B1 expression could be
present in cells with rs2307842. Further work is needed to
understand the relevance and functional consequences of
this common polymorphism in CLL patients. Of note, our
study shows that the presence of variants that alter the 3′
UTR-site targeted by the miRNA could be an alternative
mechanism to the presence of mutations inside or sur-
rounding microRNA genetic loci.
Although miR-223 has been related to HSP90 in osteo-
sarcoma [47], miR-223 function is not well characterized
in CLL. However the expression levels significantly de-
crease with the progression of the disease and miR-223
downregulation has been associated with higher tumor
burden, disease aggressiveness, and poor prognostic fac-
tors, such as IGHV unmutated genes (UM CLL) [8,13,14].
Despite the proven implication of miR-223 expression in
CLL prognosis, little is known about the molecular mech-
anisms that may be responsible for the poor outcome of
CLL patients showing miR-223 downregulation and,unlike other miRNAs with prognostic value in CLL, such
as miR-181b and miR-29c, the target of miR-223 in CLL is
still unknown [48,49]. Our results confirmed the down-
regulation of miR-223 in IGHV UM CLLs. Moreover, the
present results, demonstrating that HSP90B1 is a direct
target gene of miR-223, provide more information about
how the downregulation of miR-223 could determine the
poor outcome of IGHV UM CLLs, possibly by upregula-
tion of HSP90B1 expression (Figure 2B and C). Limited
data are available regarding the expression of HSP90 in
CLL. In myelodisplastic syndromes, high levels of HSP90
were associated with shorter survival and increased risk of
progression into acute myeloid leukemia (AML) [50,51].
In AML, the percentage of HSP90-positive cells was cor-
related with that of Bcl2-positive cells and higher expres-
sion of HSPs was associated with lower complete
remission rate and poor survival [52,53]. Of note, we also
observed a correlation between HSP90B1 and BCL2 over-
expression in CLL patients (data not shown). HSP90 has
been proposed to have a role in the modulation of apop-
tosis and is implicated in the resistance of leukemic cells
to chemotherapeutic agents and recent evidence suggests
that HSP90 inhibitors such as 17-AAG and 17-DMAG
[23], which have shown preclinical efficacy, could be a
therapeutic option in CLL [25]. More importantly, our
data suggest that HSP90B1 overexpression is independ-
ently predictive of shorter time to first therapy in CLL
(Table 2).
Conclusions
Our study highlights the relevance of miRNAs as
critical players in the pathogenesis of CLL and shows
for the first time that miR-223 modulates HSP90B1
expression in B lymphocytes of CLL. These results
provide a plausible explanation of why CLL patients
harboring miR-223 downregulation are associated with
a poor outcome. Our work also points out HSP90B1
overexpression as a new pathogenic mechanism in
CLL and a promising therapeutic target, at least in a
subgroup of CLL patients.
Additional files
Additional file 1: Supplementary Method.
Additional file 2: Tables S1-S5.
Additional file 3: Figure S1. Differential expression of HSP90B1 in purified
paired samples (CD19+ and non- CD19) from CLL patients assessed by
qRT-PCR analysis. Box plots show the relative upregulation of HSP90B1
in B lymphocytes (CD19+ fraction cell, CD19+) from CLL patients with
rs2307842 (VAR-CLLs) compared with the non- CD19+ fraction cell
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